TrialSignal transduction and targeted therapy2024

Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.

Haoran Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.